CD274 and non-small cell lung carcinoma: Therefore, to make atezolizumab cost-effective compared with BSC, this study recommends the implementation of the PAP strategy for the PD-L1 TC ≥ 1% stage II – IIIA group in patients after postoperative adjuvant chemotherapy for stage IB-IIIA resectable NSCLC; reducing the price of atezolizumab to less than 45% of the original price through price negotiations might make the drug cost-effective for patients with stage IB-IIIA resectable NSCLC.